In spite of plummeting valuation, 23andMe still aims to pivot into biotech
Podcast: Marketplace TechPublished On: Tue Feb 13 2024
Description: 23andMe has seen its valuation plummet from $6 billion to close to zero, with the Nasdaq threatening to delist the company’s stock. Still, company leaders have high hopes for medical research and a pivot to biotech. Rolfe Winkler has been writing about what happened for The Wall Street Journal, and discussed the company’s financial woes and future roadmap with Marketplace’s Lily Jamali.
The note was deleted
The note was saved
Your message was sent